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To date, the rate of detection of autoinflammatory gene mutations in patients suspected of having
an autoinflammatory disorder is very low. However, most of these data refer to pediatric populations.
The relative rarity and lack of information on adult-onset autoinflammatory diseases make it likely that
mutations will be found in an even smaller percentage of cases. Our aim was to develop and validate a set of
variables for predicting the risk that a given adult patient presenting with recurrent fever episodes carries
mutations in the MEFVor TNFRSFIA genes, in order to increase the probability of obtaining positive
results on genetic testing. One hundred and ten consecutive patients with a clinical history of periodic fever
attacks were screened for mutations in the TNFRSFIA and the MEFVgenes. The mean age at disease onset
was 27.85 years. Detailed information about each patient's family history, personal history, and clinical
manifestations were retrospectively collected. A diagnostic score was constructed based on univariate
and multivariate analysis in a randomly-selected dataset (training set; n=40). The score was validated on
an independent set of the remaining patients (validation set; n=70). Age at onset (odds ratio [OR] 0.958,
P =0.050), positive family history of recurrent fever episodes (OR 5.738, P = 0.006 ), thoracic pain (OR
7.390, P= 0.002), abdominal pain (OR 2.853, P= 0.038) and skin involvement (OR 8.241, P= 0.003) were
independently correlated with a positive genetic test result. A diagnostic score was calculated using the
linear combination of the estimated coefficients of the logistic model (cut off equal to 0.24) revealing high
sensitivity (0.94), high specificity (0.94) and high accuracy (0.94). We have identified variables that appear
to be strongly related to the probability of detecting gene mutations in MEF and TNFRSFIA in adults, thus
improving the evaluation or patients with suspected autoinflammatory disorders.
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Familial Mediterranean fever (FMF) (Mendelian
Inheritance in Man; MIM no.#249I 00) and tumor
necrosis factor receptor-associated periodic
fever syndrome (TRAPS; MIM no. #142680)
are respectively the most common autosomal
recessive and autosomal dominant monogenic
autoinflammatory disorders, and are caused by
mutations of genes encoding proteins that are
involved in the regulation or activation of the
inflammatory response (1).
Both FMF and TRAPS are characterized by
recurrent episodes of fever variably associated with
abdominal and chest pain, arthralgias and/or arthritis,
cutaneous manifestations and lymphadenopathy.
FMF attacks typically last from I to 3 days, while
TRAPS attacks usually last more than 1 week.
Overlapping symptoms complicate their differential
diagnosis. Both conditions are characterized by
disease flares separated by symptom-free intervals
of variable duration with complete normalization of
acute phase reactants.
The genes responsible for FMF and TRAPS
are respectively the MEFV gene, which encodes
a protein called pyrin (2-3), and the TNFRSFJA
gene, which encodes the 55-kD receptor for tumor
necrosis factor (TNF)-a (4). Mutations causing
FMF are present at a very high frequency in several
populations, and the disease is most prevalent in the
Mediterranean basin and Middle East (5), whereas
TRAPS shows no ethnic predilection. Both diseases
are more frequently diagnosed in the pediatric
population, but FMF onset in adulthood, (6-7) and
adult-onset TRAPS (8) have also been described.
To date, the rate of detection of autoinflammatory
gene mutations in patients suspected of having an
autoinflammatory disorder is very low, less than 20%
in case series. However, most of these data refer to
pediatric populations (9-10). The relative rarity and
lack of information on adult-onset autoinflammatory
diseases make it likely that mutations will be found
in an even smaller percentage of cases. We are
currently screening for possible autoinflammatory
diseases in our Rheumatology Department, and
are monitoring predominantly adult patients
with genetically confirmed diagnoses. We have
developed and provided preliminary validation for
a set of variables that may predict the probability
that a given adult patient presenting with recurrent
fever episodes carries mutations in the MEFV or
TNFRSFJA genes, with the aim of increasing the
probability of obtaining positive results with genetic
testing.
MATERIALS AND METHODS
Patients
The study was conducted using data from 2 patient
samples. A training sample was randomly selected
from the initial screening group and used to create the
diagnostic model. A separate validation sample was then
used to validate the diagnostic model in an independent
patient population.
The training and validation sets were randomly
selected from among all patients meeting the inclusion
criteria; each patient had the same probability of being
included in the training or validation group.
All patients enrolled were seen between November
2007 and June 2009 at our Institution, and were part
of a larger cohort of 487 patients treated for recurrent
periodic fever attacks. Of these, 216 were excluded
from the present study for one or more of the following
reasons: I) lack of complete clinical information 2) not
meeting the inclusion criteria. In addition, the results of
a genetic analysis of the two genes under study (MEFV,
TNFRSFJA), and complete clinical information were
available for 11 0 of the remaining 271 patients. Detailed
information about family history, personal history, and
clinical manifestations were collected retrospectively.
Criteria for inclusion in the screening group were: I)
periodic fever attacks of unknown origin, with fever- and
symptom-free intervals associated with normal levels of
acute-phase reactants, and 2) one or more of the following
symptoms present during fever attacks: abdominal pain,
chest pain, Lymphadenopathy (documented by imagine
techniques: echotomography and/or magnetic resonance
imaging and/or high resolution computed tomography
which were performed in order to role out underlying
disorders), splenomegaly (echotomographic evaluation),
cutaneous manifestations, musculoskeletal involvement,
oral aphtosis, ocular involvement (periorbital oedema
and/or conjunctivitis), orchitis. A total of 110 consecutive
patients were enrolled in the screening group, 40 ofwhom
were randomly entered in the training sample and 70 of
whom were randomly entered in the validation sample.
For FMF, homozygous and compound heterozygous
patients were considered to be genetically positive, while
for TRAPS, heterozygous patients were considered to
be genetically positive. All patients were Caucasians, of
Italian ancestry. The study was approved by the Ethics
Board of the Azienda Ospedaliera Universitaria Senese,
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Siena, Italy. Each patient had previously provided written
consent for genetic testing, in accordance with the Helsinki
Declaration and local Ethics Committee regulations, and
also provided written consent for inclusion in the study.
DNA extraction
Mononuclear cells were purified from the peripheral
blood of healthy donors and patients (with informed
consent) by density gradient centrifugation on Ficoll-
Paque (Amersham Biosciences, Buckinghamshire, UK).
Genomic DNA was isolated from the peripheral blood
lymphocytes of patients and healthy controls using
QIAamp DNA mini Kit (Qiagen, Hilden Germany).
Genomic DNA amplification and mutation detection
The TNFRSFJA gene exons 2, 3, 4 and 6, which
encode the extracellular domain of the 55 kD receptor
for TNF-a, and the MEFV gene exons 2, 3, 5 and 10,
where the majority of known mutations are found (11),
were amplified by polymerase chain reaction (PCR) using
Expand High Fidelity PCR System (Roche, Germany).
PCR products were purified using the Wizard SV Gel
and PCR Clean-Up System (Promega, Madison, WI,
USA). Sequencing was carried out on the ABI 3730 DNA
analyzer (Bio-Fab Research srI, Italy) using the same
primers as those used for PCR.
Statistical methods
The primary aim of diagnostic score construction was
to distinguish patients who were likely to have positive
results on genetic testing from those who were likely to
test negative, and therefore would not need to undergo
genetic testing. As a secondary and exploratory objective,
we attempted to assess the most logical order in which the
genetic tests should be performed in patients who, after
the first step, are determined to be at high risk.
The data are expressed as absolute frequencies and
percentages (%). The association between the variables
under consideration and the presence of mutations (the
outcome) was evaluated by t test or chi square test,
depending on the type of the variable (numerical or
categorical). To optimize the model's predictive capacity,
the original matrix was randomly divided, by a random
number generator, into two sub-matrixes (learning and
testing) and all the candidate variables were arranged
in a dichotomous manner. Univariate logistic regression
analysis was performed to identify the variables that
were significantly associated with positive genetic test
results. Variables yielding p values of less than 0.05 were
entered into a multivariate logistic analysis in which
positivity of the genetic test was the dependent variable.
Stepwise forward-backward logistic regression was
used in the learning set for the inclusion of variables.
The minimization error was evaluated with receiver
operating characteristic (ROC) curves, which assessed the
performance of the model in the learning and training set.
Model parameters were estimated in the learning set, and
predictive performance evaluation was done in the testing
set. Odds ratios (OR) and 95% confidence intervals (95%
CI) were calculated for each risk factor as exponential
of variable coefficients (beta). The risk classes were
constructed through classification criteria based on
sensitivity and specificity. In particular, the cut-off value
suggested by ROC analysis was defined as the point that
gave an optimal level of sensitivity and specificity.
In order to determine which genetic test should be
performed first, the probability that a patient belongs
to a particular risk class was calculated based on values
for the independent variables. For this purpose, the
diagnostic score was calculated by assigning a weight to
each variable according to the beta coefficients estimated
by the logistic model and then combining them in a linear
fashion. Only symptoms that were correlated at a 5%
significance level with a specific disease category in the
univariate analysis by chi square test were included as
continuous variables in the regression tree analysis. A
p value < 0.05 (2-tailed) was considered statistically
significant. All statistical analyses were performed with
the software packages SPSS version 13.0 (SPSS, Inc.,
Chicago, II) and MatLab version 7.0.1 (The MathWorks
Inc. Natick, Ma).
RESULTS
At the time of genetic testing, the majority of
the patients (82.0%) were over the age of 16 (mean
32.26 years [range 3-68 yearsD. The mean age at
disease onset was 27.85 years (range 2-65 years).
A total of 92 patients did not have mutations in
the regions of the 2 genes examined, whereas 18
patients were identified as having homozygous or
compound heterozygous mutations in MEFV (6
patients; 2 in the training set and 4 in the validation
set) or heterozygous mutations in TNFRSFIA (12
patients; 5 in the training set and 7 in the validation
set). Table I summarizes the frequencies of clinical
manifestations in the patients with positive genetic
tests. Since none of the patients enrolled (0/110)
showed orchitis, orchitis was not included in the
statistical evaluation.
After the screening procedure was completed, 40
of the 110 patients were included in the training set.
Table II shows the findings of the univariate logistic
regression analysis (with positive genetic test results
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Table I. Clinical characteristics ofpatients with positive results on genetic testing.
Independent variable TNFRSFlA (n=12) MEFV(n=6) No mutations (n= 92)
Abdominal pain 5 (41.66%) 4 (66.66%) 16 (17.39%)
Thoracic pain II (91.66%) 3 (50%) 28 (30.43%)
Skin Rash 4 (33.33%) 5 (83.33%) 14 (15.22%)
Musculoskeletal involvement 6 (50%) 5 (83.33%) 63 (68.48%)
Ocular involvement 1(8.33%) 0 19 (20.65%)
Periorbital edema 1(8.33%) 0 8 (8.70%)
Headache 1(8.33%) I (16.66%) 19 (20.65%)
Lymphadenopathy 1(8.33%) 3 (50%) 21 (22.83%)
Age at onset (> 16 yrs) 9 (75%) 2 (33.33%) 78 (84.78%)
Positive family history 6 (50%) 0 9 (9.78%)
Duration offever (> 7 days) 4 (33.33%) 0 46 (50%)
Oral aphtosis 1(8.33%) I (16.66%) 20 (21.74%)
Splenomegaly 2 (16.66%) 2 (33.33%) 22 (23.91%)
Orchitis
as the dependent variable) and the variables retained
in the final multivariate model. All symptoms were
studied in univariate analysis as binary variables
(presence or absence of symptoms). The ROC curve
for the training set, with a cutoff equal to 0.24,
indicated a sensitivity of 0.912, a specificity of0.960
and an accuracy of0.955 (Fig. lA). This cutoffvalue
guaranteed high sensitivity and good specificity. A
total of 70 patients were enrolled in the validation
set. The ROC curve in the validation set indicated
a sensitivity of 0.944, a specificity of 0.939 and an
accuracy of 0.938 (Fig. IB).
The variables retained in the final model were re-
coded according to the frequency (never, sometimes,
often, always) of clinical manifestations (abdominal
pain, chest pain, skin rash) and according to risk
class (age at onset, positive family history) in order
to achieve the best fit (Table III). The codes (never,
sometimes, often, and always) refer to each episode
of fever and not to the time between attacks. After
re-coding, a diagnostic score was calculated using
the linear combination of the estimated coefficients
of the logistic model and the new coding as follows:
SCORE = -0.043 x age + 1.049 x abdominal pain
+ 2 x thoracic pain + 2.109 x skin rash + 1.747 x
positive family history
The score will be -0.043 when a patient is over
60 years of age, has a negative family history for
periodic or recurrent fever episodes and presents
no symptoms other than fever. It will be 22.078
when a patient is less than 10 years of age, has a
positive family history for recurrent fever episodes
and has all the symptoms with the highest frequency.
Standardization of scores allows the probability of
having a mutation to be expressed as a percentage,
and thus facilitates interpretation of the results
obtained. A score greater than 24% (> 5.309 points)
identifies patients at high risk of carrying mutations
lot. J. ImmuoopathoI. Pharmacol.
Table II. Estimations and p values from univariate and multivariate logistic regression analyses.
Univariate Analysis Multivariate Analysis
Independent variable OR (95% CI) p value OR (95% CI) p value
Abdominal pain 2.002 (1.264-3.170) 0.003 2.853 (1.057-7.701) 0.038
Thoracic pain 2.012 (1.301-3.112) 0.002 7.390 (2.246-24.318) 0.002
Skin Rash 1.845 (1.227-2.772) 0.003 8.241 (2.052-33.100) 0.003
Musculoskeletal involvement 0.948 (0.633-1.418) 0.793
Ocular involvement 0.761 (0.465-1.246) 0.278
Periorbital edema 0.917 (0.535-1.572) 0.752
Headache 0.913 (0.586-1.422) 0.686
Lymphadenopathy 0.96 (0.633-1.456) 0.848
Age at onset (> 16 yrs) 0.677 (0.457-1.004) 0.052 0.958 (0.917-1.000) 0.050
Positive family history 2.074 (1.351-3.184) 0.001 5.738 (1.649-19.968) 0.006
Duration offever (> 7 days) 0.629 (0.416-0.95) 0.027
Oral aphtosis 1.062 (0.707-1.597) 0.771
Splenomegaly 1.00 (0.63-1.587) 0.999
OR: odds ratio; C/: confidence interval
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in the genes under consideration, whereas a lower
percentage score « 5.309 points) indicates a low
risk. The score cut-off value was determined as the
optimal level of sensitivity and specificity, and then
standardized as a percentage. To obtain a standardized
score it is necessary to adjust the minimum score of
-0.043 to 0 and the maximum score to 22.121 and
calculate the percentage by proportions.
All patients included in the training set who
had a definite genetic diagnosis were studied with
regression tree classification analysis in order to
identify variables with predictive value for a positive
genetic test. Additionally, a univariate analysis
was used to evaluate which of the variables had
discriminating value for differentiating between
mutations in the two genes. In spite of the fact that
fever attacks lasted less than 1 week in patients with
mutations in either gene, the only variable with a
significantly different incidence between the two
genes on univariate analysis was the duration of
fever attacks (p=0.025).
DISCUSSION
The list of known hereditary periodic fever
syndromes currently includes twoautosomal recessive
conditions FMF and hyperimmunoglobulinemia D
with periodic fever syndrome (BIDS) (MKD; MIM
no.#260920), and a group of autosomal dominant
diseases, including TRAPS and the cryopyrin
associated periodic syndromes (CAPS).
Most of these diseases typically manifest in the
pediatric population, ranging from the first hours to
the first decade of life, while a limited number of
patients experience disease onset during adulthood.
Onset of HIDS is typically in the first year of life,
and genetic testing is unnecessary in patients who
have their first fever attack at age 2: 5 years (12).
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Table III. Variables included in the final modelfor the calculation ofthe diagnostic score.
Variable
Age at Onset
Abdominal
pain
Coding
Age c1ass*
Never=O
Sometimes= I
Often =2
Always=3
Beta Diagnostic Score
-0.043 -0.043 x age c1ass*
1.049 Never=O
Sometimes=1.049
Often =2.098
Always=3.147
Thoracic pain Never=O
Sometimes=1
Often =2
Always=3
2.000 Never=O
Sometimes=2
Often =4
Always=6
Skin Rash Never=O
Sometimes=1
Often =2
Always=3
2.109 Never=O
Sometimes=2.109
Often =4.218
Always=6.327
Positive family Negative=O 1.747 Negative=O
history Positive =1 Positive =1.747
*Age classes (pt): 7, <10 yrs; 6, 11-20 yrs; 5, 21-30 yrs; 4, 31-40 yrs; 3, 41-50 yrs;
2,51-60 yrs; 1, >60 yrs
CAPS are also characterized by onset in early
childhood and, in addition, their chronic disease
course and distinguishing clinical features often help
to establish a differential diagnosis (13-14). Since
our study involved mainly adult patients, only FMF
and TRAPS were considered.
Late-onset FMF is fairly rare, with 14-30%
of FMF patients manifesting the disease in late
adulthood (6-7). Advanced age, even up to age 65,
is not an exclusion criteria, as we recently reported
(15). Adult-onset FMF seems to be related to low-
penetrance mutations and, although patients may
experience milder disease, generally the clinical
manifestations are similar to those of younger
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Fig. 1. A) ROC curve for the 40 patients included in the
training set, indicating a sensitivity of0.9J2, a specificity
of 0.960 and an accuracy of 0.955. B) ROC curve for
the 70 patients included in the validation set, indicating a
sensitivity of0.944, a specificity of0.939 and an accuracy
of0.938.
patients, except that arthritis and erysipelas-like
erythema occur at significantly lower frequencies in
adults (7).
Adult onset of TRAPS, up to the age of 63,
has also been described (8, 16). As with FMF, it
is frequently related to low-penetrance mutations
(8, 16-17). Patients with adult-onset TRAPS may
be characterized by a phenotype that mimics
FMF in the duration of inflammatory attacks,
which may last less than 1 week (18). In addition,
patients with adult-onset TRAPS may present
atypical clinical manifestations, such as recurrent
pericarditis as the sole clinical manifestation (8),
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thus mimicking autoimmune disorders (8, 18-19).
Recurrent pericarditis is not rare, and we recently
proposed clinical criteria for identifying patients
who should be tested for genetic mutations of the
TNFRSF1A gene (20-21). Recently, the hypothesis
that recurrent pericarditis may belong to the group
of auto inflammatory as opposed to autoimmune
diseases has been raised (22-23), however more
basic and clinical research into the etiology of this
common and troublesome disease is needed.
In addition to the clinical criteria that we
suggested previously (20-21), our diagnostic score
may serve as an evidence-based guideline for
the diagnosis of patients with recurrent fever and
pericarditis, identifying the few patients among
them who may prove to be carriers of mutations in
"autoinflammatory genes".
Regarding the order in which genes should
be examined when an autoinflammatory disease
is suspected, helpful indications may come from
ethnicity, family history, duration of fever attacks,
and the presence of peculiar clinical manifestations.
Nevertheless, perhaps more in adulthood than in
childhood, the 2 disorders are largely overlapping,
and it is often difficult to decide which gene should
be screened first. Ethnicity may not prove useful,
since patients of Mediterranean origin affected
with TRAPS are commonly observed, and may be
characterized by a phenotype that mimics FMF (18)
in terms of fever duration, as we observed in most
of the TRAPS patients enrolled in this study (Table
I). This wide variability in the clinical presentation
of TRAPS may lead to incorrect clinical suspicions,
wrong diagnosis and improper management.
Recently, a diagnostic score for improving
genetic diagnosis of recurrent periodic fever in
children under the age of 10 has been proposed that
increases the probability ofobtaining positive results
in genetic testing and reduces the cost of molecular
analysis (24). However, this pediatric diagnostic
score could not distinguish our genetically-positive
adult patients from genetically-negative patients:
most of the subjects who carried mutations in the
TNFRSF1A gene were identified as low-risk patients.
This was probably related to the fact that most of the
patients carrying mutations in the TNFRSF1A gene
were characterized by incomplete disease.
Federici et al. also performed a study on a large
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group of adult patients, and suggested that meeting
FMF criteria (25) and being of Mediterranean
origin should be considered clear indications for
recommending molecular analysis of the MEFV
gene. The authors also underlined that in the absence
of these features or in the presence of a negative
genetic test for mutations in the MEVF gene, the next
gene to be screened should be chosen on the basis
of expert advice (25). Of note, we could not apply
these recommendations to our cohort since all of
our patients were of Italian origin, thus multivariate
analysis could not evaluate the ethnic origin of
patients among the possible discriminating variables.
Nevertheless, ethnic origin should obviously be taken
into consideration when patients from populations
with a high prevalence ofmutations ofa certain gene
are examined (25). The same is true in the case of
patients who meet diagnostic criteria for FMF (26).
In conclusion, we propose a diagnostic score for
evaluating adults with recurrent fever attacks that
may be useful for identifying those at high risk for
carrying mutations in the MEFV and TNFRSFJA
genes. In particular, we have identified abdominal
and thoracic pain, skin manifestations, young age
at onset and positive family history of periodic
fever syndromes as being variables that appear to
correlate strongly with the probability of detecting
gene mutations in MEFV or TNFRSFJAin adults,
thus improving the evaluation of patients with
suspected autoinflammatory disorders. Nevertheless,
further evaluation including more patients, different
populations and using longitudinal studies are
needed to verify the sensitivity and specificity of the
proposed score.
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